Ixekizumab improves disease severity, clinical symptoms and quality of life in patients with genital psoriasis: a 24‐week real‐life experience

2021 ◽  
Author(s):  
Gianluca Calianno ◽  
Maria Esposito ◽  
Rosaria Fidanza ◽  
Maria Palmieri ◽  
Maria Concetta Fargnoli
Keyword(s):  
Quality Of Life ◽  
Disease Severity ◽  
Life Experience ◽  
Clinical Symptoms ◽  
Real Life ◽  
Genital Psoriasis

scholarly journals Patient-Reported Outcomes, Health-Related Quality of Life, and Clinical Outcomes for Urothelial Cancer Patients Receiving Chemo- or Immunotherapy: A Real-Life Experience

2021 ◽  
Vol 10 (9) ◽  
pp. 1852
Author(s):  
Gry Assam Taarnhøj ◽  
Henriette Lindberg ◽  
Christoffer Johansen ◽  
Helle Pappot
Keyword(s):  
Quality Of Life ◽  
Cancer Patients ◽  
Patient Reported Outcomes ◽  
Life Experience ◽  
Locally Advanced ◽  
Neoadjuvant Treatment ◽  
Real Life ◽  
Oncological Treatment ◽  
Patient Reported

Patients with urothelial cell carcinoma (UCC) often have comorbidities, which cause trouble for the completion of oncological treatment, and little is known about their quality of life (QoL). The aim of the present study was to obtain and describe patient-reported outcomes (PRO) and QoL data from UCC patients in the treatment for locally advanced muscle-invasive or metastatic UCC. A total of 79 patients with UCC completed four questionnaires (EORTC QLQ-C30, QLQ-BLM30, HADS, and select PRO-CTCAE™ questions) once weekly during their treatment. From those, 26 patients (33%) underwent neoadjuvant treatment for local disease while 53 patients (67%) were treated for metastatic disease. Of all patients, 54% did not complete the planned treatment due to progression, nephrotoxicity, death, or intolerable symptoms during treatment. The five most prevalent PRO-CTCAE grade ≥ 2 symptoms were frequent urination (37%), fatigue (35%), pain (31%), dry mouth (23%), and swelling of the arms or legs (23%). The baseline mean overall QoL was 61 (±SD 24) for all patients (neoadjuvant (73, ±SD 19) and metastatic (54, ±SD 24)) and remained stable over the course of treatment for both groups. A stable overall QoL was observed for the patients in this study. More than half of the patients did not, however, complete the planned treatment. Further supportive care is warranted for bladder cancer patients.

scholarly journals A New Curcuma Extract (Flexofytol®) in Osteoarthritis: Results from a Belgian Real-Life Experience

2014 ◽  
Vol 8 (1) ◽  
pp. 77-81 ◽  
Author(s):  
Thierry Appelboom ◽  
Nathalie Maes ◽  
Adelin Albert
Keyword(s):  
Quality Of Life ◽  
Patient Satisfaction ◽  
Observational Study ◽  
Life Experience ◽  
Real Life ◽  
Randomized Controlled ◽  
Randomized Controlled Studies ◽  
Patient Pain ◽  
Inflammatory Drugs

This retrospective observational study summarizes the experiences of 820 patients treated with a new Curcuma extract (Flexofytol®, 4-6 capsules per day), for more than 6 months for various forms of painful osteoarthritis. These experiences were reported by 110 Belgian general practitioners via a questionnaire that included quality-of-life parameters for assessing patient experience. Data were submitted to an independent statistician for analysis. Within the first 6 weeks, Flexofytol® improved patient pain, articular mobility, and quality of life. Excellent tolerance was reported, and more than half of these patients were able to discontinue analgaesic and anti-inflammatory drugs. Patient satisfaction was confirmed by their decision to maintain Flexofytol® therapy for more than 6 months. These data must be confirmed with randomized controlled studies. We currently conclude that Flexofytol® which is based on a new preparation of curcumin, is as a potential neutraceutical for the care of patients complaining of joint problems, with excellent tolerance and rapid benefits for articular mobility, pain, and quality of life.

scholarly journals Real-life experience of quality of life, treatment satisfaction, and adherence in patients receiving oral anticoagulants for atrial fibrillation

2018 ◽  
Vol Volume 12 ◽  
pp. 79-87 ◽  
Author(s):  
Michaël Benzimra ◽  
Béatrix Bonnamour ◽  
Martin Duracinsky ◽  
Christophe Lalanne ◽  
Jean-Pierre Aubert ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Atrial Fibrillation ◽  
Treatment Satisfaction ◽  
Life Experience ◽  
Oral Anticoagulants ◽  
Real Life

scholarly journals Effectiveness of Benralizumab in Improving the Quality of Life of Severe Eosinophilic Asthmatic Patients: Our Real-Life Experience

2021 ◽  
Vol 12 ◽  
Author(s):  
Giulia Scioscia ◽  
Giovanna Elisiana Carpagnano ◽  
Carla Maria Irene Quarato ◽  
Donato Lacedonia ◽  
Sonia Santamaria ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Function ◽  
Asthma Control ◽  
Severe Asthma ◽  
Life Experience ◽  
Real Life ◽  
Eosinophilic Inflammation ◽  
Eosinophilic Asthma ◽  
Severe Eosinophilic Asthma

Background: Severe eosinophilic asthma decreases lung function and causes worsen symptoms, often forcing recurrent maintenance corticosteroid use. The aim of our real-life study was to evaluate the effectiveness of an add-on treatment with benralizumab in patients with severe eosinophilic asthma, paying particular attention to the impact on their quality of life (QoL).Materials and methods: In this prospective study, 10 outpatients with severe eosinophilic asthma were added-on with benralizumab and followed-up in our severe asthma clinic after 12 and 24 weeks. At each patient visit, pre-bronchodilator FEV1 and inflammatory markers were recorded. Variations in asthma symptoms control and QoL perception was assessed by validated questionnaires.Results: All the subjects experienced a marked reduction of nocturnal and diurnal symptoms over time and were able to stop using OCS, as documented by the improvement in Asthma control test (ACT) and Asthma Control Questionnaire score. Similarly, we recorded a statistically significant increase in patient’s QoL perception in EQ-VAS, EQ-5D-3L and Asthma Quality of Life Questionnaire (AQLQ) assessment (p < 0.05). Simultaneously we recorded a significant reduction in eosinophilic inflammation, an improvement in pre-bronchodilator FEV1. These results appear to be in line with those already obtained in the previous randomized controlled trials (RCTs).Conclusion: Our 24-weeks real life experience supports the effectiveness of an add-on treatment with benralizumab in reducing eosinophilic inflammation and OCS-use, increasing lung function and improving control of nocturnal and diurnal symptoms, as well as restoring severe asthma patients to a better QoL.

Effectiveness of the EQ-5D and CRES-4 questionnaire for assessing the impact on the quality of life of patients and the level of satisfaction after exchanging dicumarinics for edoxabán: Real-life experience based on a multicentre study

2021 ◽  
Author(s):  
Francisco J. Guerrero-Márquez ◽  
Ignacio Sainz-Hidalgo ◽  
Pablo Cristobo Sainz ◽  
Inmaculada Sigler Vilches ◽  
Alberto Avilés Toscano ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Multicentre Study ◽  
Life Experience ◽  
Real Life ◽  
Level Of Satisfaction ◽  
The Impact

Psoriasis Lessens Quality of Life Regardless of Disease Severity

2006 ◽  
Vol 37 (8) ◽  
pp. 13
Author(s):  
KERRI WACHTER
Keyword(s):  
Quality Of Life ◽  
Disease Severity

Quality of life in HCV patients treated with OBV/PTV/r ± DSV ± RBV under real-life conditions – Data from the German observational study LIFE-C

2018 ◽  
Vol 56 (01) ◽  
pp. E2-E89
Author(s):  
P Buggisch ◽  
R Link ◽  
U Naumann ◽  
G Teuber ◽  
R Heyne ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Observational Study ◽  
Real Life ◽  
Life Conditions
Sign in / Sign up

Export Citation Format

Share Document